Program announces first round of participants
TORONTO, May 30, 2013 /CNW/ - The first three companies selected to
participate in the MaRS EXCITE program aim to improve outcomes for
breast cancer, sleep apnea and drug-resistant hypertension.
The Excellence in Clinical Innovation and Technology Evaluation (EXCITE)
initiative helps companies accelerate the adoption and reimbursement of
innovative health technologies through a single, harmonized,
pre-market, evidence-based process.
EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna
Diagnostics Inc. as the program's initial participants. "MaRS' EXCITE
program works with industry experts in close collaboration with the
Ontario healthcare system and leading academic health centres to
develop path-breaking protocol designs and implement new partnerships,"
said Ilse Treurnicht, CEO, MaRS Discovery District. "We are delighted
to now bring these innovative technologies one step closer to improving
the health and well-being of Ontarians. In addition, the health system
is providing critical validation for Ontario's leading medtech
innovations, which in turn will enable adoption elsewhere."
EXCITE selects technologies primarily based on their potential to
substantially improve clinical outcomes for patients or lower system
costs, compared with current approaches.
EXCITE is privileged to have involvement from academia, the provincial
health system - including clinicians - the medical technology industry,
and the Ontario government. Working with this diverse group of partners will allow EXCITE to provide participants with relevant, early
information on how their innovations would be implemented and used in
patient care. By collaborating with companies in the pre-market stage,
improvements can be integrated early in the product life cycle when
redevelopment is still possible.
"EXCITE will enable Ontarians to have faster and improved access to
innovative new health care technologies that will help to ensure
patients receive the right care, at the right time, in the right place
- a key pillar of our government's Action Plan for Health Care," said
Deb Matthews, Minister of Health and Long-Term Care.
"Today's announcement is a promising step towards helping Ontarians get
faster access to new health technologies," said Reza Moridi, Minister
of Research and Innovation. "Ontario is committed to making smart
research and innovation investments that can lead to life-saving
discoveries. This is why we are a hub for life science research and the
largest life sciences region in Canada. I am proud to see our
investments creating jobs, strengthening the economy and most
importantly improving quality of life."
The Toronto Health Economics and Technology Assessment (THETA)
initiative, based at the University of Toronto, and The Applied Health
Research Centre (AHRC) at St. Michael's Hospital will lead the clinical
studies for these first three EXCITE technologies. These studies are
large provincial clinical trials with embedded health economics and
systematic review components. The THETA initiative will evaluate the
technologies for Rna Diagnostics and ApneaDx. The AHRC will be
evaluating Medtronic of Canada's device. Both of these centres have
demonstrated experience and excellence in clinical trials methodology,
health technology assessment and in conducting complex, multi-centre
trials with proven capacity for data collection, synthesis and
"Medtronic of Canada is enthusiastic to be participating in the
pioneering MaRS EXCITE program with our SymplicityTM Renal Denervation Catheter System," said Neil Fraser, President,
Medtronic of Canada Ltd. "Through its evaluation of Symplicity, EXCITE
will develop the economic evidence to determine the applicability and
cost-effectiveness required by the Ontario health system to make the
appropriate decisions on the adoption of this novel, cost-effective,
and clinically-proven technology that has the potential to benefit
Ontarians suffering from pharmacotherapy-resistant hypertension."
ApneaDx Inc. has created an easy-to-use, affordable home-based device for
diagnosing sleep apnea, a condition characterized by abnormal (or
cessation of) breathing during sleep. Sleep apnea is also associated
with a high risk of heart attack and stroke. Currently, it is estimated
that 85 per cent of sleep apnea cases are undiagnosed. The ApneaDx
Portable Home Sleep Apnea Device allows patients to collect quality
data about their breathing patterns in their own home, reducing the
burden on overnight sleep clinics.
Medtronic of Canada Ltd helps patients suffering from pharmacotherapy-resistant hypertension
with its SymplicityTM Renal Denervation System. This minimally invasive treatment delivers
low-level radiofrequency energy through the renal artery wall to
achieve renal denervation, substantially lowering blood pressure1 and reducing long-term complications and overall medical visits.2 The system was reviewed and approved under Health Canada's Policy on
Priority Review of Medical Device Licence Applications, as it provides
substantial evidence of safety and efficacy for effective treatment in
the prevention of a serious, life-threatening condition that is not
adequately managed in Canada.
Rna Diagnostics Inc. has developed the RNA Disruption Assay (RDATM), a promising diagnostic tool that identifies breast cancer patients
who are not responding to chemotherapy treatments. This device could
alert clinicians to treat non-responsive patients with alternate
therapies, directing patients toward more effective treatments sooner,
and sparing them the potential adverse side effects of chemotherapy.
A world first, MaRS' Excellence in Clinical Innovation and Technology
Evaluation (EXCITE) is an evaluation platform that accelerates the
adoption of breakthrough medical technologies by prioritizing only the
best, most cost-effective technologies and helping them obtain the
evidence they need for federal licensing and provincial health system
EXCITE helps these technologies navigate the system and get to market -
and to patients - faster by providing:
An early indication of fit with the healthcare system;
Evidence in time to make technology improvements; and
Harmonized studies that support licensing and adoption decisions.
EXCITE is made possible through province-wide collaboration and
leadership. Key stakeholders comprising EXCITE's Management Board
include research hospitals (CAHO), the provincial government (MOHLTC,
MRI/MEDTE), industry (MEDEC and HTX), the health system (OHTAC) and
About MaRS Discovery District
MaRS Discovery District (@MaRSDD) is a mission-driven innovation centre located in Toronto. MaRS works
with partners to catalyze, accelerate and amplify innovation. MaRS
supports entrepreneurs building Canada's next generation of growth
companies. In the last three years, MaRS startup clients have raised
over $750 million in capital, earned over $375 million in revenue and
hired well over 3,500 workers into knowledge economy jobs.
1Symplicity HTN-1 Investigators, Durability of Blood Pressure Reduction
Out to 24 Months Catheter-Based Renal Sympathetic Denervation for
Resistant Hypertension, Hypertension 2011;57;911-917; originally published online Mar 14, 2011.
2 Geisler BP, MD, MPH, Egan BM, MD, Cohen JT, PHD, Garner AM, MS, Akehurst
RL, MFPHM, Esler MD, MBBS, PHD, Pietzsch JB, PHD, Cost-Effectiveness
and Clinical Effectiveness of Catheter-Based Renal Denervation for
Resistant Hypertension, Journal of the American College of Cardiology, 2012, 0735-1097.
SOURCE: MaRS Discovery District
For further information:
Manager, Media & Community Relations
MaRS Discovery District
416.673.8100 ext. 2710